NICE says no to conditionally-approved Pixuvri
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, is not recommending Cell Therapeutics' Pixuvri (pixantrone) for non-Hodgkin B-cell lymphoma. In preliminary draft guidance issued 11 April, the institute says there is not enough evidence to support the drug.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.